Parameter
Managing the transition to central bank digital currency
The effect of new housing supply in structural models: a forecasting performance evaluation
MPI Corporation's Advanced Semiconductor Test Division Achieves Fully Traceable RF Calibration Breakthrough Up to 110 GHz
BRAUNSCHWEIG, Germany, Jan. 24, 2024 /PRNewswire/ -- MPI Corporation's Advanced Semiconductor Test (AST) Division, a pioneer in on-wafer testing solutions, today announced a landmark achievement in RF calibration technology.
- BRAUNSCHWEIG, Germany, Jan. 24, 2024 /PRNewswire/ -- MPI Corporation's Advanced Semiconductor Test (AST) Division, a pioneer in on-wafer testing solutions, today announced a landmark achievement in RF calibration technology.
- Collaborating with the Physikalisch-Technische Bundesanstalt (PTB) in Germany, the division has successfully achieved full traceability in characterizing a commercially-available calibration substrate up to 110 GHz and set a new industry benchmark.
- This achievement, spearheaded by Dr. Andrej Rumiantsev, Director of RF Technology at MPI-AST, represents a significant leap for the entire RF product line provided by MPI product line.
- The fully traceable characterization paves the way for more accurate, reliable, and universally accepted high-frequency measurements, essential for cutting-edge technologies like 5G.
MPI Corporation's Advanced Semiconductor Test Division Achieves Fully Traceable RF Calibration Breakthrough Up to 110 GHz
BRAUNSCHWEIG, Germany, Jan. 24, 2024 /PRNewswire/ -- MPI Corporation's Advanced Semiconductor Test (AST) Division, a pioneer in on-wafer testing solutions, today announced a landmark achievement in RF calibration technology.
- BRAUNSCHWEIG, Germany, Jan. 24, 2024 /PRNewswire/ -- MPI Corporation's Advanced Semiconductor Test (AST) Division, a pioneer in on-wafer testing solutions, today announced a landmark achievement in RF calibration technology.
- Collaborating with the Physikalisch-Technische Bundesanstalt (PTB) in Germany, the division has successfully achieved full traceability in characterizing a commercially-available calibration substrate up to 110 GHz and set a new industry benchmark.
- This achievement, spearheaded by Dr. Andrej Rumiantsev, Director of RF Technology at MPI-AST, represents a significant leap for the entire RF product line provided by MPI product line.
- The fully traceable characterization paves the way for more accurate, reliable, and universally accepted high-frequency measurements, essential for cutting-edge technologies like 5G.
Emission Monitoring System Market worth $5.0 billion by 2028 - Exclusive Report by MarketsandMarkets™
For this reason, many countries have implemented regulations that require continuous monitoring and measurement of actual emission levels.
- For this reason, many countries have implemented regulations that require continuous monitoring and measurement of actual emission levels.
- A company hires trained service providers to install, operate, and maintain an emission monitoring system.
- Continuous emission monitoring systems are expected to hold a substantial market share during the forecast period.
- North America is expected to hold a significant market share of the emission monitoring system industry during the forecast period.
Emission Monitoring System Market worth $5.0 billion by 2028 - Exclusive Report by MarketsandMarkets™
For this reason, many countries have implemented regulations that require continuous monitoring and measurement of actual emission levels.
- For this reason, many countries have implemented regulations that require continuous monitoring and measurement of actual emission levels.
- A company hires trained service providers to install, operate, and maintain an emission monitoring system.
- Continuous emission monitoring systems are expected to hold a substantial market share during the forecast period.
- North America is expected to hold a significant market share of the emission monitoring system industry during the forecast period.
Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
Despite this staggering number, there are currently no federally approved treatments targeting the genetic roots of these disorders.
- Despite this staggering number, there are currently no federally approved treatments targeting the genetic roots of these disorders.
- The goal of developing gene therapy to treat intellectual disabilities fuels both Justus and Dr. Gargus.
- We envision a future where intellectual disabilities are not barriers but challenges we can overcome,” said Justus.
- “NeuroQure’s mission is not merely scientific advancement; it’s a beacon of hope for individuals and families affected by these conditions.”
CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting
These peer-reviewed abstracts demonstrate the scientific validation and utility of CareDx products and solutions.
- These peer-reviewed abstracts demonstrate the scientific validation and utility of CareDx products and solutions.
- The hybrid capture approach to matching is unique to CareDx and gives labs flexibility in gene content and increased robustness over other methodologies.
- Ahmed Mostafa, MD, PhD, Director, Technical Supervisor, and Clinical Consultant, Histocompatibility and Immunogenetics Laboratory, St. Paul's Hospital—Saskatoon.
- Virtual Crossmatching and Epitope Analysis as Informational Aids in the Transplant Decision Making Process: A Review of VXMatch and VECTR.
Real-World Evidence and Data Analytics Conference (Frankfurt, Germany - October 5-6, 2023): Paving the Path for Next-Gen Medicinal Research
DUBLIN, Sept. 29, 2023 /PRNewswire/ -- The "Real-World Evidence and Data Analytics Conference" set to take place on October 5th and 6th, 2023, in Frankfurt, Germany has been added to ResearchAndMarkets.com's offering.
- DUBLIN, Sept. 29, 2023 /PRNewswire/ -- The "Real-World Evidence and Data Analytics Conference" set to take place on October 5th and 6th, 2023, in Frankfurt, Germany has been added to ResearchAndMarkets.com's offering.
- Building on five triumphant installments held in Boston, USA, this year's European chapter promises an invigorating assembly of experts, leaders, and stakeholders.
- The confluence aims to shed light on the accelerating evolution of real-world evidence (RWE) and its vital impact on drug benefit elucidation.
- Its pivotal role in patient monitoring through digital platforms, coupled with aiding clinical data organization for regulatory inclusions, is noteworthy.